Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management.

Autor: Tasso R; Dipartimento di Medicina Sperimentale (DIMES); Università degli Studi di Genova, Genova, Italy; UO Oncologia Cellulare, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Marconi S; Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: silvia.marconi@hsanmartino.it., Rossi G; UOC Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genova C; UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Dipartimento di Medicina Interna e Specialità Mediche (DiMI); Università degli Studi di Genova, Genova, Italy., Coco S; Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2023 Jul; Vol. 28 (7), pp. 103616. Date of Electronic Publication: 2023 May 18.
DOI: 10.1016/j.drudis.2023.103616
Abstrakt: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. Circulating elements have gained significant interest in the diagnosis and prognosis of NSCLC patients. Among these, platelets (PLTs) and their derived extracellular vesicles (P-EVs) are emerging eligible biosources both in terms of number and carriers of genetic materials (RNA, proteins, and lipids). PLTs are mainly produced by the shedding of megakaryocytes and together with P-EVs, participate in a variety of pathological processes including thrombosis, tumor progression, and metastasis. Here, we performed an extensive literature review focusing on PLTs and P-EVs as potential diagnostic, prognostic, and predictive markers for NSCLC patient management.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: